Mai L - Search Results

1

Successful management of prostate cancer with bulky pelvic lymph node metastases after rapid development of castration-resistant prostate cancer: a case report with review of the literature.

Mai L, Li Y, Yang P, Zhang Z, Wu J, Zhou F, Liu Y, He L. Mai L, et al. Transl Androl Urol. 2020 Jun;9(3):1428-1436. doi: 10.21037/tau-20-725. Transl Androl Urol. 2020. PMID: 32676427 Free PMC article.

2

Impact of Time to Castration Resistance on Cytoreductive Radiotherapy in Metastatic Castration-Resistant Prostate Cancer.

Mai L, Zhang Z, Li Y, Liu R, Li J, Huang S, Lin M, Liu B, Cao W, Wu J, Liu M, Zhou F, Liu Y, He L. Mai L, et al. Front Oncol. 2020 Dec 4;10:606133. doi: 10.3389/fonc.2020.606133. eCollection 2020. Front Oncol. 2020. PMID: 33344256 Free PMC article.

3

Survival Outcomes and Prognostic Analysis Following Greater Cytoreductive Radiotherapy in Patients With Metastatic Prostate Cancer.

Zhang Z, Wei M, Mai L, Li Y, Wu J, Huang H, Huang S, Lin M, Jiang X, Zhou F, Liu M, Liu Y, He L. Zhang Z, et al. Among authors: mai l. Front Oncol. 2020 Sep 30;10:549220. doi: 10.3389/fonc.2020.549220. eCollection 2020. Front Oncol. 2020. PMID: 33102216 Free PMC article.

4

Cytoreductive radiotherapy combined with abiraterone in metastatic castration-resistance prostate cancer: a single center experience.

Liu Y, Long W, Zhang Z, Mai L, Huang S, Liu B, Cao W, Wu J, Zhou F, Li Y, He L. Liu Y, et al. Among authors: mai l. Radiat Oncol. 2021 Jan 6;16(1):5. doi: 10.1186/s13014-020-01732-y. Radiat Oncol. 2021. PMID: 33407637 Free PMC article.

5

Metastasis-directed stereotactic body radiotherapy for oligometastatic renal cell carcinoma: extent of tumor burden eradicated by radiotherapy.

Liu Y, Long W, Zhang Z, Zhang Z, Mai L, Huang S, Han H, Zhou F, Dong P, He L. Liu Y, et al. Among authors: mai l. World J Urol. 2021 Nov;39(11):4183-4190. doi: 10.1007/s00345-021-03742-1. Epub 2021 May 27. World J Urol. 2021. PMID: 34043023 Free PMC article.

6

Locoregional recurrence after nephrectomy for localized renal cell carcinoma: Feasibility and outcomes of different treatment modalities.

Liu Y, Zhang X, Ma H, Tian L, Mai L, Long W, Zhang Z, Han H, Zhou F, Dong P, He L. Liu Y, et al. Among authors: mai l. Cancer Med. 2022 Dec;11(23):4430-4439. doi: 10.1002/cam4.4790. Epub 2022 May 4. Cancer Med. 2022. PMID: 35506551 Free PMC article.

7

Stereotactic body radiotherapy in combination with non-frontline PD-1 inhibitors and targeted agents in metastatic renal cell carcinoma.

Liu Y, Zhang Z, Liu R, Wei W, Zhang Z, Mai L, Guo S, Han H, Zhou F, He L, Dong P. Liu Y, et al. Among authors: mai l. Radiat Oncol. 2021 Nov 2;16(1):211. doi: 10.1186/s13014-021-01937-9. Radiat Oncol. 2021. PMID: 34727963 Free PMC article.

8

[Studies on the chemical constituents of the leaves of Lantana camara].

Pan WD, Mai LT, Li YJ, Xu XL, Yu DQ. Pan WD, et al. Among authors: mai lt. Yao Xue Xue Bao. 1993;28(1):35-9. Yao Xue Xue Bao. 1993. PMID: 8328268 Chinese.

9

[Studies on triterpenoid constituents of the roots of Lantana camara].

Pan WD, Li YJ, Mai LT, Ohtani KH, Kasai RT, Tanaka O, Yu DQ. Pan WD, et al. Among authors: mai lt. Yao Xue Xue Bao. 1993;28(1):40-4. Yao Xue Xue Bao. 1993. PMID: 8328269 Chinese.

10

[Studies on chemical constituents of the roots of Lantana camara].

Pan WD, Li YJ, Mai LT, Ohtani K, Kasai R, Tanaka O. Pan WD, et al. Among authors: mai lt. Yao Xue Xue Bao. 1992;27(7):515-21. Yao Xue Xue Bao. 1992. PMID: 1442083 Chinese.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

795 results

Search Page

Filters